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Abstract
Objectives Alzheimer’s disease (AD) and frontotemporal
(FTD) dementia can be differentiated using [18F]-2-deoxy-2-
fluoro-D-glucose (FDG)-PET. Since cerebral blood flow
(CBF) is related to glucose metabolism, our aim was to inves-
tigate the extent of overlap of abnormalities between AD and
FTD.
Methods Normalized FDG-PET and arterial spin labelling
(ASL-MRI)-derived CBF was measured in 18 AD patients
(age, 64±8), 12 FTD patients (age, 61±8), and 10 controls
(age, 56±10). Voxel-wise comparisons, region-of-interest
(ROI), correlation, and ROC curve analyses were performed.
Results Voxel-wise comparisons showed decreased CBF and
FDG uptake in AD compared with controls and FTD in both
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precuneus and inferior parietal lobule (IPL). Compared with
controls and AD, FTD patients showed both hypometabolism
and hypoperfusion in medial prefrontal cortex (mPFC). ASL
and FDG were related in precuneus (r=0.62, p<0.001), IPL
(r=0.61, p<0.001), and mPFC across groups (r=0.74,
p<001). ROC analyses indicated comparable performance
of perfusion and metabolism in the precuneus (AUC, 0.72
and 0.74), IPL (0.85 and 0.94) for AD relative to FTD, and
in the mPFC in FTD relative to AD (both 0.68).
Conclusions Similar patterns of hypoperfusion and
hypometabolism were observed in regions typically associat-
ed with AD and FTD, suggesting that ASL-MRI provides
information comparable to FDG-PET.
Key Points
• Similar patterns of hypoperfusion and hypometabolism were
observed in patients with dementia.
• For both imaging modalities, parietal abnormalities were
found in Alzheimer’s disease.
• For both imaging modalities, prefrontal abnormalities were
found in frontotemporal dementia.
Keywords PerfusionMRI . Positron-emission tomography .
18F-FDG . Alzheimer’s disease . Frontotemporal dementia
Introduction
Alzheimer’s disease (AD) and frontotemporal dementia
(FTD) are among the most common types of dementia, and
both are characterized by progressive impairment of cogni-
tive, behavioural, and daily functioning [1, 2]. Early in the
course of the disease in particular, clinical presentation of
FTD and ADmay overlap or may be misdiagnosed as another
psychiatric or neurological disorder. Brain glucose metabo-
lism measured using [18F]-2-deoxy-2-fluoro-D-glucose (18F-
FDG) positron emission tomography (PET) provides impor-
tant additional diagnostic information about brain function
[3]. Glucose metabolism reflects neuronal (dys)function,
which is thought to be an early marker of dementia, preceding
structural magnetic resonance imaging (MRI) findings such as
cortical atrophy and clinical symptoms [4]. Bilateral temporal
and parietal glucose hypometabolism is present in patients
with AD of mild severity [5–7]. In contrast, patients with
FTD show marked hypometabolism in the prefrontal cortex
(PFC) [8–10]. For this reason, FDG is able to accurately dif-
ferentiate between AD and FTD [3, 7, 11] with a high level of
specificity [12, 13].
The disadvantages of PET include radiation exposure and
the relatively high cost. A potential alternative to FDG-PET is
the assessment of cerebral blood flow (CBF) measured by
perfusion MRI, as CBF is thought to be closely related to
metabolism [14]. CBF can be measured non-invasively using
arterial spin labelling (ASL), whichmakes use ofmagnetically
labelled water in the arterial blood supply as an endogenous
tracer [15, 16]. Indeed, comparisons between CBF measured
with ASL and single-photon emission computed tomography
provided almost equivalent diagnostic information in AD
[17]. As such, like FDG, ASL may be suitable to identify
unique disease-related patterns.
Among the advantages of ASL are its relatively short ac-
quisition time, low cost, lack of radiation exposure, non-inva-
siveness, and easy incorporation into standard MRI protocols.
ASL studies in patients with AD have shown lower CBF in
parietal and temporal regions and in the posterior cingulate
cortex (PCC) [18–21], very similar to findings with FDG. In
FTD, lower levels of CBF were found in the right frontal
regions in comparison to controls, while higher CBF levels
were found in the temporal-parietal regions and PCC com-
pared to AD [22, 23].
The first study directly comparing FDG and ASL between
patients with AD and healthy subjects showed corresponding
deficits primarily in the angular gyrus and PCC [24, 25]. As
such, ASL may have potential clinical use in the diagnostic
workup of dementia.While ASL sequences could be available
in nearly every hospital equipped with MRI, perfusion maps
are not yet commonly used for diagnostic decision-making.
ASL is also a relatively new technique and needs further val-
idation against the more established FDG-PET. Before ASL
can serve as a more solid biomarker for differential diagnosis
in single subjects, several dementia types must first be com-
pared at a group level with ASL compared to FDG imaging.
To date, no study has compared ASL with FDG in FTD, or
compared FTD with AD together with its discriminative per-
formance. The use of a retrospective design allowed us to
investigate brain function in patients with a mild disease state
while ensuring that a clinical diagnosis was maintained at
approximately two years. Therefore, the aim of this study
was to compare FDG (metabolism) and ASL (perfusion) im-
aging in the same subjects, andmore importantly, to determine
the extent of overlap with regard to aberrant brain function
between the imaging techniques.
Methods
Subjects
A convenience sample comprising 18 patients with AD, 12
patients with behavioural-variant FTD, and 10 controls with
available FDG and ASL images from the Amsterdam Demen-
tia Cohort were included [26]. Subjects were eligible if the
interval between FDG and ASL examinations was 6 months
or less. All patients visited the VU University Medical Centre
outpatient memory clinic between October 2010 and October
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2012. All underwent standardized dementia screening: medi-
cal history, neuropsychological assessment, physical and neu-
rological examinations, laboratory testing, and a structural
brain MRI. Clinical diagnosis was established by consensus
among a multidisciplinary team prior to PET imaging, and
without knowledge of the ASL data.
AD patients fulfilled the National Institute of Neurological
and Communicative Disorders and Stroke/Alzheimer’s Dis-
ease and Related Disorders Association criteria for probable
AD [27]. Alzheimer’s pathology was verified in all AD pa-
tients using non-displaceable binding potential parametric im-
ages based on 90-min dynamic Pittsburgh Compound-B (PIB)
PET scans. All FTD patients met the criteria for probable
behavioural-variant FTD [28]. AD and FTD patients were
eligible if the diagnosis was maintained over a clinical
follow-up period of at least 1 year. Controls were patients with
subjective memory complaints who lacked verified cognitive
disorders or any relevant psychiatric disorders, and who
showed no evidence of neurodegenerative disorder on MRI
[19]. In addition, controls were required to have normal CSF
Aß1-42 levels in order to exclude possible preclinical AD
cases.
The study was approved by the Medical Ethics Review
Committee, and all subjects provided written informed
consent.
PET
Fifteen minutes prior to injection, patients were instructed to
rest with their eyes closed and wearing earplugs in a dimly lit
room with minimal background noise. Forty-five minutes af-
ter intravenous bolus injection of 188±8 MBq 18F-FDG, pa-
tients underwent a 15-min emission examination (3×5-min
frames). FDG emission scans were obtained using a Gemini
TF 64 PET-CT (Philips Medical Systems, Cleveland, OH,
USA) or ECAT EXACT HR+ (Siemens/CTI, Knoxville,
TN, USA) scanner (AD, n=6/n=12; FTD, n=7/n=5; controls
n=3/n=7, respectively). Details with respect to image acqui-
sition have been described elsewhere [29]. All PET unrecon-
structed data (sinograms) were normalized and corrected for
random events, dead time, scatter, and decay. Attenuation cor-
rection was performed using a low-dose CT (PET-CT) or
transmission scan (ECAT HR+). The reconstruction protocol
has been described elsewhere [30], but included standard re-
construction algorithms for both systems (ECAT HR+: stan-
dard filtered back-projection; PET-CT 3D row-action maxi-
mum likelihood algorithm). Finally, standardized uptake
values (SUVs) were calculated, normalized for injected dose
and body weight and length, using an in-house-developed
software tool for kinetic and parametric analysis of dynamic
PET studies. SUV images were normalized to global uptake
using SPM8 (Statistical Parametric Mapping; Wellcome Trust
Centre for Neuroimaging, London, UK).
MRI
MR images were acquired on a 3 T whole-body MR system
(Signa HDxt; GE Medical Systems, Milwaukee, WI, USA)
using an 8-channel head coil. The MRI acquisition protocol
has been extensively described elsewhere [19], and included a
sagittal 3D T1-weighted inversion recovery fast spoiled gra-
dient echo. ASL-MRI sequencing was provided by GE.
Pseudo-continuous ASL perfusion images (3D fast spin-
echo acquisition with background suppression; post-label de-
lay, 2.0 s; repetition time [TR]=9 ms; echo time [TE]=4.8 s;
spiral readout, 8 arms×512 samples; 36×5.0 mm axial slices;
3.2×3.2 mm2 in-plane resolution; reconstructed pixel size,
1.7×1.7 mm2; acquisition time, 4 min) were calculated after
subtracting labelled from control images. Both T1-weighted
and ASL images were corrected for gradient non-linearity in
all three directions. Perfusion was normalized to global perfu-
sion using SPM8, as described for FDG.
Image analysis
Pre-processing and between-group image comparisons were
performed using SPM8 in MATLAB (MathWorks, Release
2010a). Parametric images of FDG-SUV and ASL-derived
CBF were co-registered to the structural T1 image, and spa-
tially registered to the Montreal Neurological Institute (MNI)
space (voxel size, 2.0×2.0×2.0 mm3) [31]. ASL images were
spatially smoothed using an 8-mm full-width-at-half-
maximum Gaussian kernel corresponding to the smoothing
kernel of FDG images at reconstruction. Group effects were
investigated separately for ASL and FDG with a voxel-wise
contrast including covariates (age and sex) to adjust for com-
mon confounding effects [32]. To reliably and validly com-
pare normalized signals of the techniques in grey matter, pro-
portional scaling, mean global calculation, and grey matter
masking was applied in SPM8. Because we were interested
in the concordance of spatial abnormality patterns and corre-
sponding standard normal deviate relative to controls, SPM-
derived mean z-scores were extracted from multiple signifi-
cant clusters (thresholded at p<0.001, uncorrected for multi-
ple comparisons [cluster size≥10]).
To investigate the extent to which FDG and ASL were
correlated, region-of-interest (ROI) analyses were performed.
Based on the most significant clusters derived from patient-
versus-control comparisons that (partially) overlapped be-
tween FDG and ASL, post hoc ROI analysis was performed
using MarsBaR (MARSeille Boîte À Région d'Intérêt [Mar-
seille Region of Interest Toolbox]) (v 0.43, Marseille, France).
Functional ROIs encompassed both FDG and ASL regional
abnormal clusters at a liberal threshold (defined through SPM
local maxima p<0.05 uncorrected), ensuring a target region of
adequate size.
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In total, three separate ROIs were created for AD (n=2) and
FTD (n=1) signature regions (Supplementary Fig. 2). ROI
coordinates for AD were as follows: precuneus (xyz ASL
−10/−68/30, FDG −2/−70/32) and inferior parietal lobule
(IPL) (xyz ASL 44/−56/46, FDG 46/−58/40). ROI coordi-
nates for FTD were mPFC (xyz ASL 2/62/6, FDG 6/60/6).
Next, a combined (ASL+FDG) signature ROI was saved as a
single cluster, and trimmed with a box (20×20×20 mm3) at
intermediate voxel coordinates (precuneus: −6/−69/31, IPL:
45/−57/43, mPFC: 4/61/6). Trimming was done to remove
extraneous voxels (i.e. outside signature region). ROI values
were extracted with default settings.
Statistical analysis
Demographic and clinical data were analysed using SPSS
software (IBM SPSS Statistics for Windows Version 20.0;
IBM Corp., Armonk, NY, USA). If data deviated from nor-
mality (using Kolmogorov-Smirnov tests for non-normality),
non-parametric tests were used, as indicated. Demographic
data (age, weight, and body length) and MMSEwere assessed
using analysis of variance (ANOVA). Gender differences
were assessed using χ2 tests. Across groups, the relationship
between FDG and ASL was investigated using the Pearson
correlation.
Across-group (AD, FTD, controls) comparative perfor-
mance was investigated using binary logistic regression, with
all FDG and ASL ROI values entered simultaneously as input,
and a dummy-coded dementia group as dependent variable.
Multicollinearity assumptions were investigated using linear
regression methods. Further, to investigate the extent to which
FDG and ASL were able to discriminate between AD and
FTD, receiver operating characteristic (ROC) curves were
generated to obtain an area under the curve (AUC). Specifi-
cally, separate ASL and FDG ROI values from AD and FTD
patients were used as input (test variable); the dementia group
was set as state variable. In addition, mean difference scores of
signature ROIs were calculated to determine whether
subtracting signature regions would result in better discrimi-
native performance.
Results
Demographic and clinical variables are presented in Table 1.
Age, gender, time intervals, and FDG SUV normalization
variables (body weight and length, injected dose) did not dif-
fer among groups. Likewise, there was no difference in fre-
quency distribution of PET systems (PET-CT and HR+)
among the groups (χ2(2)=1.6, p=0.21). The combined de-
mentia groups showed lower MMSE scores (F[38, 1])=1.8,
p=0.01) than controls, but did not differ between each other.
All amyloid PET scans of the AD patient group were
classified as consistent with abnormal amyloid load. All
FTD patients had normal cerebrospinal fluid (CSF) Aß1-42
levels (n=3) or negative amyloid PETscan (n=8). In one FTD
patient, amyloid-specific information was missing. Figure 1
shows raw ASL and FDG images with corresponding MRI of
a typical AD and FTD patient.
Figure 2 shows regional abnormalities derived from group
comparisons projected onto anMNI glass brain, while Fig. 3A
shows z-scores for FTD and AD compared to controls (MNI
coordinates with corresponding cluster sizes are displayed in
Supplementary Table 2). In AD compared to controls, both
lower metabolism (FDG) and lower perfusion (ASL) were
found in the bilateral precuneus, bilateral inferior parietal lob-
ule (IPL), and dorsolateral prefrontal cortex (DLPFC). In ad-
dition, AD patients showed lower perfusion in the
orbitofrontal cortex (OFC). Compared with controls, FTD pa-
tients showed both lower metabolism and lower perfusion in
mPFC, OFC, and temporal poles. In addition, hypoperfusion
was found in the supplementary motor area (SMA) and
hypometabolism in the DLPFC in FTD. Overall, mean age-
and sex-adjusted z-scores (reflecting normal deviates) were
comparable between ASL and FDG in patient groups relative
to controls.
Compared with FTD patients, patients with AD showed
lower metabolism in the precuneus and bilateral IPL, while
lower perfusion was observed in the precuneus and left IPL
(Fig. 3B). In addition, lower perfusion was found in the mid-
dle temporal gyrus (MTG) with AD compared to FTD, with
the opposite pattern in the SMA, OFC, temporal poles, and
mPFC. Likewise, lower metabolism was found in the OFC,
SMA, mPFC, temporal poles, and anterior PFC (aPFC) in
FTD relative to AD.While OFC hypometabolism was located
in anteromedial orbitofrontal regions, hypoperfusion was
found predominantly in posterolateral regions, extending to
the temporal poles.
Correlations between regional FDG and ASL values are
shown in Fig. 4. Across groups, a strong correlation between
FDG and ASL was found in mPFC (r=.74, p<0.001;
Fig. 4A), IPL (r=.61, p<0.001; Fig. 4B), and precuneus
(r=.62, p<0.001).
The predictive value of the separate ROIs ([IPL, precuneus,
mPFC]×FDG+ASL) in all groups (AD, FTD, controls) for
AD and FTDwas investigated using logistic regression. There
was a significant fit of the data in AD (χ2(6)=44.1, p<0.001)
predicted by IPL metabolism (β±SE, 0.54±0.31, p =0.046),
but not by IPL (β±SE, 0.71±0.31) or precuneus (β±SE, 0.88
±0.12) perfusion, or precuneus (β±SE, 0.94±0.1113) metab-
olism. Testing was performed to exclude significant
multicollinearity, and showed no violations (all variables: tol-
erance>0.41, VIF<2.46). In contrast, for FTD, there was a
significant fit of the data (χ2(6)=32.1, p<0.001) predicted
by mPFC perfusion (β±SE, 0.74±0.16, p=0.026), but not
mPFC (β±SE, 0.89±0.15) metabolism. Multicollinearity
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testing showed no violations (all variables: tolerance>0.40,
VIF<2.52).
To investigate the discriminative power of ASL and FDG
for AD and FTD, ROC curves were generated. Figure 5 shows
ROC curves for AD and FTD based on precuneus (Fig. 5A)
and mPFC (Fig. 5B) ROI values. Precuneus AUC was 0.74
for FDG and 0.72 for ASL. For IPL, the AUC was 0.94 for
FDG and 0.85 for ASL. For mPFC, the AUC was 0.68 for
both FDG and ASL. Additionally, ratios (between mPFC and
precuneus, and mPFC and IPL) were used for discriminating
AD from FTD, which showed AUC values of 0.80 and 0.90
for the precuneus, and 0.89 and 0.96 for the IPL for FDG and
ASL, respectively. Likewise, for discriminating FTD from
AD, mPFC showed an AUC of 0.82 for FDG and 0.89 for
ASL.










Age in years (SD) 64 (8) 61 (8) 56 (10) F(37,2)=1.9, p=0.17
Gender 61 % male 42 % male 90 % male χ2(2)=5.5, p=0.06
MMSE (SD) 24 (4) 24 (4) 27 (3) F(37,2)=2.6, p=0.09
Median years of complaints (interquartile range)* 2.0 (1.9) 2.3 (1.9) n.a. U=101.5, p=0.78
Scan interval in months (SD) 2.1 (1) 2.2 (2) 1.9 (2) F(37,2)=.8, p=0.5
FDG SUV normalization variables
Body
Weight in kg (SD) 78 (11) 75 (15) 86 (17) F(37,2)=2.2, p=0.13
Length in cm (SD) 176 (9) 169 (10) 175 (9) F(37,2)=1.5, p=0.23
Injected dose in MBq (SD) 190 (8) 187 (8) 188 (7) F(37,2)=.97, p=0.39
Abbreviations: cm centimetre, kg kilogram, MBq megabecquerel, SD standard deviation, SUV standardized uptake value
*Obtained through interviews with relatives of patients
Fig. 1 Transversal FDG and ASL images of an FTD (first and second
rows, MMSE 26) and an AD (third and fourth rows, MMSE 17) patient
with early-onset disease. Both transversal planes show predominantly
prefrontal abnormalities in FTD and parietal abnormalities in AD. Red
colour reflects normal metabolism and perfusion
Fig. 2 Functional brain abnormalities of AD and FTD compared to
controls projected onto a MNI glass brain. Predominantly parietal,
precuneus aberrant function is visible in AD compared to controls,
while FTD compared to controls shows mostly prefrontal abnormalities
with both FDG and ASL. For illustrative purposes, images were
thresholded at p<0.005
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Discussion
In this study, FDG and ASL were compared between AD and
FTD patients. The main finding of this study was that similar
spatial abnormalities in glucose metabolism and perfusion
were seen in AD and FTD patients compared with cognitively
normal subjects in areas consistent with disease models. Over-
all, these findings reinforce the role for ASL in assessing spa-
tial patterns of aberrant brain function in dementia, and sug-
gest the potential for use in memory clinics.
To date, quantitative and qualitative FDG studies in AD
have consistently demonstrated glucose hypometabolism in
the bilateral temporal-parietal and precuneal regions AD
[5–7], which are associated with neuropsychological deficits
[33] and structuralMRI atrophy [34]. The present FDG results
on AD are in line with previous reports, indicating severely
abnormal metabolism, especially in bilateral IPL.
The present study also demonstrated ASL hypoperfusion in
bilateral IPL in patients with AD compared with controls,
consistent with a previous study using voxel-wise analyses
[21]. In another study, unilateral IPL hypoperfusion was seen
[20], possibly as a result of globally decreased perfusion [19].
Hypoperfusion was also observed in the bilateral precuneus in
AD patients compared with controls. These results are all in
line with voxel-wise ASL studies in AD reporting decreased
CBF in the PCC and parietal cortex compared with controls
[18–21].
With regard to FTD, metabolic impairment, often asym-
metric, has been reported in the frontal, basal ganglia, anterior
cingulate cortex, and temporal regions [7–9]. The present
FDG results are partially in line with these existing reports,
as hypometabolismwas observed in the frontal lobes and tem-
poral poles but not in basal ganglia. One possible explanation
may relate to the fact that subcortical metabolic deficits are
Fig. 3 Panel A shows FDG and
ASL regional mean z-scores of
AD (left) and FTD (right)
compared to controls. Panel B
shows AD < FTD (left) and FTD
< AD (right) perfusion and
metabolism abnormalities
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associated with advanced disease states [9, 10] or comorbid
motor neuron disease [8]. In the present study, however,
behavioural-variant FTD patients who were included were
primarily those with mild dementia.
In FTD compared to controls, functional abnormalities in
the frontal lobe were found with ASL, consistent with previ-
ous studies [22, 23]. While some studies have demonstrated
bilateral [23] and right [22] frontal deficits, the present find-
ings predominantly point to dorsomedial prefrontal hypoper-
fusion. Previous neuroanatomical discrepancies may be
explained by the finding that specific prefrontal functional
abnormalities are associated with different behavioural FTD
characteristics [35].
Overall, similar functional deficits were found in AD and
FTD with both FDG and ASL, and these are consistent with
well-known pathophysiological disease models [4, 28, 35].
The two imaging techniques showed comparable discrimina-
tive performance in terms of AUC. For AD signature ROIs,
FDG showed slightly larger AUCs than ASL, whereas the
opposite was found if we took the mean difference between
Fig. 4 Positive correlations between FDG SUVand ASL derived CBF in (A) medial prefrontal cortex (right, r=.74, p<0.001) and (B) inferior parietal
lobule (left, r=.61, p<0.001) across groups
Fig. 5 ROC curves for FDG and ASL in AD and FTD. A) Precuneus function for ASL and FDG in discriminating AD from FTD. B) mPFC function in
discriminating FTD from AD. Ratios were taken between the mPFC and precuneus and entered into ROC analyses as ‘ratio ROI’
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AD and FTD ROIs. For AD, the IPL showed slightly better
differentiation from FTD compared to the precuneus with both
FDG and ASL. In addition, regression analyses indicated that
IPL metabolism was the strongest predictor for AD compared
to all other ROIs, versus ASL prefrontal perfusion in FTD.
Nevertheless, regional FDG and ASL values were correlated
in the precuneus, IPL, and, most clearly, in the frontal lobe
across groups. In contrast, voxel-wise abnormalities were
most comparable in AD versus controls, and to a lesser extent
in FTD. This might be caused by distinct and broad frontal
deficiencies known to be present in FTD. To date, only one
study has been reported in which a voxel-wise comparison
between ASL and FDG was performed in AD. Chen et al.
showed overlapping functional abnormalities in the PCC
and angular gyri [24]. The present results endorse those find-
ings, but additionally provide first evidence of largely over-
lapping functional abnormalities in imaging techniques for
FTD already at an early stage with only mild disease severity.
The current findings further demonstrate comparable discrim-
inatory ability for FDG and ASL between the two most com-
mon early-onset dementia groups.
While overlapping ASL perfusion abnormalities relative to
FDG were demonstrated at a group level, future studies are
necessary to clarify the clinical potential of this application for
single subjects, while also controlling for common confound-
ing effects. The capabilities of ASL should also be investigat-
ed in more complex dementia cases or variants, or even in
other neuropsychiatric disorders. In addition, to ensure general
use, performance should be tested on different MRI systems.
Lastly, for potential clinical use, visualization and assessment
of CBF maps could benefit from scientific agreement on
smoothing kernels for optimal signal-to-noise ratio.
Functional brain imaging may be hampered by partial vol-
ume effects (PVE) that can occur due to cerebral atrophy. Since
our primary aim was to compare imaging technique perfor-
mance in such a way that it could be extrapolated to a realistic
clinical setting, our data was uncorrected for PVE. We there-
fore cannot distinguish true decreases in brain tissue perfusion
and metabolism from apparent decreases in brain function due
to atrophy. However, even though partial volume corrections
(PVCs) were not performed CBF has been determined previ-
ously both with and without PVC across several dementia
groups [36]. Binnewijzend and colleagues (2014) showed that
after PVC, CBF consistently increased, but proportional differ-
ences remained similar across groups. Furthermore, there are
concordant reports of functional brain abnormalities persisting
after PVC in AD and FTD [37–39]. In addition, similar pro-
cessing pipelines were used for FDG and ASL in the current
study, and applying these corrections could have introduced
unwanted variability in key brain regions. At this time, no ideal
PVCs are available for either ASL or FDG [40].
This study had several other potential limitations. We used
a convenience sample comprising patients with extensive
differential diagnoses, which may have biased our results in
that clear-cut cases (i.e. FDG scan not necessary) were not
included. For this reason, not all FTD patients exhibited
frontotemporal atrophy on MRI. Notwithstanding this issue,
the study did show overlapping aberrant function already in
cases with mild disease severity, which renders it suitable for
early diagnosis. Another limitation was that subjects with cog-
nitive complaints but without any verified abnormalities were
used as a reference group, which consisted primarily of males.
Despite statistically adjusting analyses for gender effects, this
might have influenced our results. On the other hand, Liu and
colleagues showed no specific regional hypoperfusion related
to gender effects [32]. It is thus likely that our regional abnor-
malities do reflect dysfunction related to AD and FTD pathol-
ogy. Furthermore, current knowledge is limited with regard to
brain function in healthy subjects with cognitive complaints,
although one could argue that more rigorously defined con-
trols might be ‘healthier’ than the ‘normal’ elderly population,
and that our control group better reflects clinical practice.
Lastly, many uncontrolled factors such as smoking and caf-
feine intake may have affected measurements to a certain
extent.
In conclusion, comparable reduced cerebral perfusion and
metabolism were observed, predominantly in the parietal cor-
tex and PCC in AD and in the frontal lobes in FTD, in line
with pathophysiological disease models. As such, ASL can be
considered as a promising adjunct to clinical investigations,
even for early diagnosis.
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